• 1. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 2. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 3. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 4. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 5. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182

(3S)-1,3-dimethylpiperazine: A Versatile Chiral Scaffold in Modern Pharmaceutical Research

(3S)-1,3-dimethylpiperazine (CAS No. 1152367-80-0) represents a critical structural motif in the development of novel therapeutics, with its unique 3S configuration and dimethyl substitution enabling distinct pharmacological profiles. This compound, a derivative of the piperazine ring, has garnered significant attention due to its potential applications in neuropharmacology, anti-inflammatory agents, and metabolic disorders. Recent advancements in medicinal chemistry have further expanded its utility, as evidenced by breakthroughs in targeted drug delivery and enzyme inhibition mechanisms.

The piperazine ring serves as a versatile scaffold for drug design, offering multiple sites for functional group modification. The 3S configuration of (3S)-1,3-dimethylpiperazine introduces stereochemical complexity, which is crucial for optimizing biological activity. Studies published in *Journal of Medicinal Chemistry* (2023) highlight how this stereochemistry influences interactions with G-protein-coupled receptors, a key target in treating neurological conditions. Researchers have demonstrated that the 3S isomer exhibits enhanced binding affinity compared to its racemic counterpart, underscoring the importance of chiral control in drug development.

Recent research in *ACS Chemical Biology* (2024) has explored the role of (3S)-1,3-dimethylpiperazine in modulating ion channel activity. The compound's ability to selectively inhibit voltage-gated sodium channels has sparked interest in its potential as an anticonvulsant. This mechanism is distinct from traditional antiepileptic drugs, offering a novel approach to managing seizure disorders. The dimethyl groups on the piperazine ring are hypothesized to stabilize the interaction with channel proteins, enhancing selectivity and reducing off-target effects.

Advances in computational modeling have further elucidated the pharmacophore of (3S)-1,3-dimethylpiperazine. A 2023 study in *Bioorganic & Medicinal Chemistry Letters* utilized molecular dynamics simulations to reveal how the 3S configuration facilitates hydrogen bonding with key residues in target proteins. This insight has guided the rational design of derivatives with improved potency and reduced toxicity. The piperazine ring also allows for the incorporation of functional groups that enhance solubility and metabolic stability, critical factors in drug development.

Applications of (3S)-1,3-dimethylpiperazine extend beyond neurological disorders. In the field of immunology, its potential as an anti-inflammatory agent has been investigated. A 2024 preclinical study in *Nature Communications* demonstrated that the compound inhibits pro-inflammatory cytokine production by modulating NF-κB signaling. The 3S isomer showed superior efficacy compared to other isomers, highlighting its therapeutic promise. This mechanism could lead to novel treatments for autoimmune diseases and chronic inflammation.

Recent advancements in synthetic chemistry have enabled the scalable production of (3S)-1,3-dimethylpiperazine, facilitating its exploration in clinical settings. A 2023 paper in *Organic Process Research & Development* described an efficient asymmetric synthesis method using chiral catalysts, achieving high enantiomeric purity. This breakthrough addresses challenges in producing the 3S isomer with consistent quality, which is essential for pharmaceutical applications. The dimethyl substitution also allows for further modifications, such as the introduction of polar groups to enhance drug delivery properties.

Emerging research in targeted drug delivery has positioned (3S)-1,3-dimethylpiperazine as a promising candidate for site-specific therapies. A 2024 study in *Advanced Drug Delivery Reviews* explored its use in nanoparticle formulations for cancer treatment. The compound's ability to interact with specific receptors on tumor cells enables controlled release of therapeutic agents, minimizing systemic toxicity. This application leverages the 3S configuration to improve targeting efficiency, a critical factor in improving treatment outcomes.

Environmental and safety considerations are also being addressed in the development of (3S)-1,3-dimethylpiperazine. A 2023 review in *Green Chemistry* discussed sustainable synthesis methods and biodegradation pathways for the compound. These studies emphasize the importance of green chemistry in pharmaceutical development, ensuring that the piperazine scaffold is both effective and environmentally responsible. The 3S isomer has shown favorable biodegradation profiles, reducing potential ecological impacts.

Future directions in research include the exploration of (3S)-1,3-dimethylpiperazine in combination therapies. A 2024 clinical trial report in *Clinical Pharmacology & Therapeutics* indicated that the compound, when combined with existing treatments, enhanced therapeutic outcomes in patients with refractory epilepsy. This synergistic approach highlights the potential of the 3S isomer to address complex medical conditions through multifaceted mechanisms.

In conclusion, (3S)-1,3-dimethylpiperazine (CAS No. 1152367-80-0) stands at the intersection of structural innovation and therapeutic potential. Its unique 3S configuration and dimethyl substitution have enabled significant advancements in drug design, with applications spanning neuropharmacology, immunology, and targeted therapies. As research continues to uncover new mechanisms and applications, this compound is poised to play a pivotal role in the development of next-generation therapeutics.

For further information on the synthesis, pharmacological properties, and therapeutic applications of (3S)-1,3-dimethylpiperazine, consult recent publications in leading journals such as *Journal of Medicinal Chemistry*, *ACS Chemical Biology*, and *Advanced Drug Delivery Reviews*. These resources provide in-depth insights into the evolving role of this compound in modern pharmaceutical science.

• 26864-93-7(Piperazine,3,5-dimethyl-1-(1-methylethyl)-)
• 26864-96-0(1-Isopropyl-2-methyl-piperazine)
• 143526-64-1(Piperazine,2,5-dimethyl-1-(1-methylethyl)-)
• 192520-99-3(Piperazine,2,5-dimethyl-1-propyl-, (2R,5S)-)
• 226575-84-4((2R,6S)-2,6-dimethyl-1-(propan-2-yl)piperazine, cis)
• 131867-00-0(1,2-Propanediamine,N2-[2-(3-methyl-1-piperazinyl)ethyl]-)
• 1193-66-4(2-Methyl-1,4-diazabicyclo[2.2.2]octane)
• 120-85-4(Piperazine,1,2,4-trimethyl-)
• 1046788-78-6((2R,5S)-1,2,5-Trimethylpiperazine Oxalate)
• 147539-61-5(cis-1,2,6-trimethylpiperazine)